Significance of anti-Jo-1 antibody's clinical stratification in idiopathic inflammatory myopathy and disease spectrum.
- Author:
Jia Chen LI
1
;
Zhan Hong LAI
1
;
Miao SHAO
1
;
Yue Bo JIN
1
;
Xiao Juan GAO
2
;
Ke ZHANG
3
;
Jing HOU
4
;
Yan Ying ZHANG
5
;
Zhan Guo LI
1
;
Yu Hui LI
1
Author Information
1. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Rheumatology and Immunology, Ningde Hospital Affiliated to Ningde Normal University, Ningde 352199, Fujian, China.
3. Department of Endocrinology, 80th Group Army Hospital of Chinese PLA, Weifang 261000, Shandong, China.
4. Department of Nephrology, Zhangjiakou First Hospital, Zhangjiakou 075041, Hebei, China.
5. Department of Rheumatology, Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen 518033, China.
- Publication Type:Journal Article
- Keywords:
Anti-histidyl tRNA synthetase antibody;
Anti-synthetase syndrome;
Connective tissue disease
- MeSH:
Humans;
Middle Aged;
Myalgia;
Myositis/epidemiology*;
Autoantibodies;
Connective Tissue Diseases;
Arthritis, Rheumatoid;
Neoplasms
- From:
Journal of Peking University(Health Sciences)
2023;55(6):958-965
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the significance of anti-histidyl tRNA synthetase (Jo-1) antibody in idiopathic inflammatory myopathies (IIM) and its diseases spectrum.
METHODS:We enrolled all the patients who were tested positive for anti-Jo-1 antibody by immunoblotting in Peking University People's Hospital between 2016 and 2022. And the patients diagnosed with anti-synthetase antibody syndrome (ASS) with negative serum anti-Jo-1 antibody were enrolled as controls. We analyzed the basic information, clinical characteristics, and various inflammatory and immunological indicators of the patients at the onset of illness.
RESULTS:A total of 165 patients with positive anti-Jo-1 antibody were enrolled in this study. Among them, 80.5% were diagnosed with connective tissue disease. And 57.6% (95/165) were diagnosed with IIM, including ASS (84/165, 50.9%), immune-mediated necrotizing myopathy (7/165, 4.2%) and dermatomyositis (4/165, 2.4%). There were 23.0% (38/165) diagnosed with other connective tissue disease, mainly including rheumatoid arthritis (11/165, 6.7%), undifferentiated connective tissue disease (5/165, 3.0%), interstitial pneumonia with autoimmune features (5/165, 3.0%), undifferentiated arthritis (4/165, 2.4%), Sjögren's syndrome (3/165, 1.8%), systemic lupus erythematosus (3/165, 1.8%), systemic vasculitis (3/165, 1.8%), and so on. Other cases included 3 (1.8%) malignant tumor patients, 4 (2.4%) infectious cases and so on. The diagnoses were not clear in 9.1% (15 /165) of the cohort. In the analysis of ASS subgroups, the group with positive serum anti-Jo-1 antibody had a younger age of onset than those with negative serum anti-Jo-1 antibody (49.9 years vs. 55.0 years, P=0.026). Clinical manifestations of arthritis (60.7% vs. 33.3%, P=0.002) and myalgia (47.1% vs. 22.2%, P=0.004) were more common in the ASS patients with positive anti-Jo-1 antibody. With the increase of anti-Jo-1 antibody titer, the incidence of the manifestations of arthritis, mechanic hands, Gottron sign and Raynaud phenomenon increased, and the proportion of abnormal creatine kinase and α-hydroxybutyric dehydrogenase index increased in the ASS patients. The incidence of myalgia and myasthenia were significantly more common in this cohort when anti-Jo-1 antibody-positive ASS patients were positive for one and more myositis specific antibodies/myositis associated autoantibodies (P < 0.05).
CONCLUSION:The disease spectrum in patients with positive serum anti-Jo-1 antibody includes a variety of diseases, mainly ASS. And anti-Jo-1 antibody can also be found in many connective tissue diseases, malignant tumor, infection and so on.
